

# Michael Buchert

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8460319/publications.pdf>

Version: 2024-02-01

44  
papers

3,011  
citations

218381

26  
h-index

253896

43  
g-index

49  
all docs

49  
docs citations

49  
times ranked

4914  
citing authors

#	ARTICLE	IF	CITATIONS
1	Onco-miR-21 Promotes Stat3-Dependent Gastric Cancer Progression. <i>Cancers</i> , 2022, 14, 264.	1.7	11
2	Combined Treatment with a WNT Inhibitor and the NSAID Sulindac Reduces Colon Adenoma Burden in Mice with Truncated APC. <i>Cancer Research Communications</i> , 2022, 2, 66-77.	0.7	5
3	Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 704-715.	1.9	10
4	Cancer stem cell marker DCLK1 reprograms small extracellular vesicles toward migratory phenotype in gastric cancer cells. <i>Proteomics</i> , 2021, 21, e2000098.	1.3	15
5	Machine learning for medical imaging-based COVID-19 detection and diagnosis. <i>International Journal of Intelligent Systems</i> , 2021, 36, 5085-5115.	3.3	22
6	EHF is essential for epidermal and colonic epithelial homeostasis, and suppresses <i>Apc</i> -initiated colonic tumorigenesis. <i>Development (Cambridge)</i> , 2021, 148, .	1.2	8
7	IL33 and Mast Cells—The Key Regulators of Immune Responses in Gastrointestinal Cancers?. <i>Frontiers in Immunology</i> , 2020, 11, 1389.	2.2	23
8	IL-33-mediated mast cell activation promotes gastric cancer through macrophage mobilization. <i>Nature Communications</i> , 2019, 10, 2735.	5.8	139
9	Repurposing the selective estrogen receptor modulator <i>bazedoxifene</i> to suppress gastrointestinal cancer growth. <i>EMBO Molecular Medicine</i> , 2019, 11, .	3.3	32
10	<i>MACROD2</i> Haploinsufficiency Impairs Catalytic Activity of PARP1 and Promotes Chromosome Instability and Growth of Intestinal Tumors. <i>Cancer Discovery</i> , 2018, 8, 988-1005.	7.7	55
11	Generation of an inducible mouse model to reversibly silence Stat3. <i>Genesis</i> , 2017, 55, e23023.	0.8	9
12	The JAK/STAT3 axis: A comprehensive drug target for solid malignancies. <i>Seminars in Cancer Biology</i> , 2017, 45, 13-22.	4.3	147
13	Inducible gene modification in the gastric epithelium of <i>Tff1-CreERT2</i> , <i>Tff2-rtTA</i> , <i>Tff3-luc</i> mice. <i>Genesis</i> , 2016, 54, 626-635.	0.8	6
14	Biochemical and Structural Insights into Doublecortin-like Kinase Domain 1. <i>Structure</i> , 2016, 24, 1550-1561.	1.6	56
15	Targeting JAK kinase in solid tumors: emerging opportunities and challenges. <i>Oncogene</i> , 2016, 35, 939-951.	2.6	173
16	Stomach-Specific Activation of Oncogenic KRAS and STAT3-Dependent Inflammation Cooperatively Promote Gastric Tumorigenesis in a Preclinical Model. <i>Cancer Research</i> , 2016, 76, 2277-2287.	0.4	33
17	A hypermorphic epithelial beta-catenin mutation facilitates intestinal tumorigenesis in mice in response to compounding WNT-pathway mutations. <i>DMM Disease Models and Mechanisms</i> , 2015, 8, 1361-73.	1.2	11
18	Glycoprotein A33 deficiency: a new model of impaired intestinal epithelial barrier function and inflammatory disease. <i>DMM Disease Models and Mechanisms</i> , 2015, 8, 805-15.	1.2	28

#	ARTICLE	IF	CITATIONS
19	Partial inhibition of gp130-Jak-Stat3 signaling prevents Wnt $\beta$ -catenin-mediated intestinal tumor growth and regeneration. <i>Science Signaling</i> , 2014, 7, ra92.	1.6	68
20	Therapeutic Inhibition of Jak Activity Inhibits Progression of Gastrointestinal Tumors in Mice. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 468-474.	1.9	31
21	150. <i>Cytokine</i> , 2014, 70, 64.	1.4	0
22	mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice. <i>Journal of Clinical Investigation</i> , 2013, 123, 767-81.	3.9	89
23	Abstract LB-262: Excessive Wnt activity is insufficient for intestinal tumor growth or regeneration without gp130/Jak2/Stat3 signaling.. , 2013, , .		0
24	Methods to Examine Tight Junction Physiology in Cancer Stem Cells: TEER, Paracellular Permeability, and Dilution Potential Measurements. <i>Stem Cell Reviews and Reports</i> , 2012, 8, 1030-1034.	5.6	35
25	Symplekin promotes tumorigenicity by up-regulating claudin-2 expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 2628-2633.	3.3	69
26	Genetic Dissection of Differential Signaling Threshold Requirements for the Wnt/ $\beta$ -Catenin Pathway In Vivo. <i>PLoS Genetics</i> , 2010, 6, e1000816.	1.5	81
27	Linking inflammation to cancer – A novel role for Stat3. <i>Cytokine</i> , 2009, 48, 44.	1.4	3
28	The Symplekin/ZONAB Complex Inhibits Intestinal Cell Differentiation by the Repression of AML1/Runx1. <i>Gastroenterology</i> , 2009, 137, 156-164.e3.	0.6	33
29	Elevated Dnmt3a Activity Promotes Polyposis in ApcMin Mice by Relaxing Extracellular Restraints on Wnt Signaling. <i>Gastroenterology</i> , 2009, 137, 902-913.e11.	0.6	34
30	Defective Claudin-7 Regulation by Tcf-4 and Sox-9 Disrupts the Polarity and Increases the Tumorigenicity of Colorectal Cancer Cells. <i>Cancer Research</i> , 2008, 68, 4258-4268.	0.4	108
31	STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. <i>Journal of Clinical Investigation</i> , 2008, 118, 1727-38.	3.9	276
32	DNA-methylation-dependent alterations of claudin-4 expression in human bladder carcinoma. <i>Carcinogenesis</i> , 2007, 28, 246-258.	1.3	79
33	$\beta$ -Catenin/Tcf-4 Inhibition After Progastrin Targeting Reduces Growth and Drives Differentiation of Intestinal Tumors. <i>Gastroenterology</i> , 2007, 133, 1554-1568.	0.6	41
34	AF6/s-afadin is a dual residency protein and localizes to a novel subnuclear compartment. <i>Journal of Cellular Physiology</i> , 2007, 210, 212-223.	2.0	27
35	Eve-3: A liver enriched suppressor of Ras/MAPK signaling. <i>Journal of Hepatology</i> , 2006, 44, 758-767.	1.8	16
36	Functional interaction between the ZO-1-interacting transcription factor ZONAB/DbpA and the RNA processing factor symplekin. <i>Journal of Cell Science</i> , 2006, 119, 5098-5105.	1.2	68

#	ARTICLE	IF	CITATIONS
37	Distinct requirements for the Sprouty domain for functional activity of Spred proteins. <i>Biochemical Journal</i> , 2005, 388, 445-454.	1.7	41
38	Ryk-deficient mice exhibit craniofacial defects associated with perturbed Eph receptor crosstalk. <i>Nature Genetics</i> , 2000, 25, 414-418.	9.4	157
39	The Junction-associated Protein AF-6 Interacts and Clusters with Specific Eph Receptor Tyrosine Kinases at Specialized Sites of Cell-Cell Contact in the Brain. <i>Journal of Cell Biology</i> , 1999, 144, 361-371.	2.3	187
40	Mutagenesis and selection of PDZ domains that bind new protein targets. <i>Nature Biotechnology</i> , 1999, 17, 170-175.	9.4	84
41	An epitope tagged mammalian/prokaryotic expression vector with positive selection of cloned inserts. <i>Gene</i> , 1997, 197, 337-341.	1.0	9
42	Useful Vectors for the Two-Hybrid System in Mammalian Cells. <i>BioTechniques</i> , 1997, 23, 396-402.	0.8	21
43	An In Vitro Assay of $\beta$ -Galactosidase from Yeast. <i>BioTechniques</i> , 1996, 20, 960-962.	0.8	81
44	Transcription factor AP-2 essential for cranial closure and craniofacial development. <i>Nature</i> , 1996, 381, 235-238.	13.7	581